Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Pfizer, Medivation, GM, and 2 Other Stocks Have Investors Talking

Page 1 of 2

After surging almost non-stop to $49 per barrel from $40, WTI futures are now 2% in the red while the broader indexes are pretty much flat in pre-market trading on the first trading day of the week.

Among the stocks in the spotlight today are Pfizer Inc. (NYSE:PFE), Medivation Inc (NASDAQ:MDVN), General Motors Company (NYSE:GM), Williams Companies Inc (NYSE:WMB), and Enterprise Products Partners L.P. (NYSE:EPD). Let’s find out why each stock has investors buzzing this morning and see how the smart money is positioned in each of the five equities.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

David Smart/Shutterstock.com

David Smart/Shutterstock.com

M&A in the Drug Sector

Pfizer Inc. (NYSE:PFE) and Medivation Inc (NASDAQ:MDVN) are each trending after the former agreed to buy the latter for $81.50 in cash per share in a transaction that values Medivation Inc (NASDAQ:MDVN) at a total enterprise value of around $14 billion. Although it is paying a premium on the deal (Medivation shares are 20% higher in the pre-market), Pfizer Inc. (NYSE:PFE) anticipates the acquisition to be immediately accretive to adjusted EPS to the tune of $0.05 in the first year after the deal is closed. The acquisition will also give Pfizer a leading position in the all-important oncology market.

Follow Pfizer Inc (NYSE:PFE)
Trade (NYSE:PFE) Now!

Ken Fisher’s Fisher Asset Management owned 31.7 million shares of Pfizer on June 30, while Jason Karp‘s Tourbillon Capital Partners reported owning a 4.7 million-share stake in Medivation as of the end of the second quarter.

Follow Medivation Inc. (NASDAQ:MDVN)
Trade (NASDAQ:MDVN) Now!

General Motors Trending Due to Lyft 

Despite investing half-a-billion dollars in the ride-sharing app, General Motors Company (NYSE:GM) apparently isn’t ready to buy Lyft yet. According to Bloomberg, Lyft has shopped itself to numerous companies in recent months, including Didi Chuxing, GM, and Uber. Of the potential suitors, many believe that GM would be the ideal candidate given the company’s previous investment in Lyft, which valued the app at around $5.5 billion. Lyft would help GM adjust to the ride-sharing/autonomous driving world and would help diversify GM’s business. Price does seem to be a sticking point, however. Lyft apparently wanted $9 billion, a price that no one is yet willing to pay. Given Uber’s dominance in the United States and Europe and Didi’s near-monopoly in China, a purchase of Lyft would not guarantee GM ride-sharing success. 65 funds in our database owned General Motors Company (NYSE:GM) at the end of the second quarter.

Follow General Motors Co (NYSE:GM)
Trade (NYSE:GM) Now!

On the next page we’ll examine the latest concerning the possible merger between Williams Companies and Enterprise Products Partners LP.

Page 1 of 2
Loading Comments...